A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy

Area of Science:

• Biomedical Engineering
• Oncology
• Drug Delivery Systems

Background:

• Prostate cancer is a significant global health challenge with limited treatment options.
• Alpha-enolase overexpression on prostate cancer cells presents a potential therapeutic target.
• Developing targeted drug delivery systems is crucial for improving treatment efficacy.

Purpose of the Study:

• To develop a targeted liposome drug delivery system for prostate cancer using the pHCT74 peptide.
• To evaluate the efficacy of pHCT74-modified liposomes loaded with doxorubicin (pHCT74-lipo-Dox) in targeting alpha-enolase.
• To assess the in vitro and in vivo anti-tumor activity of the targeted liposomes.

Main Methods:

• Construction of pHCT74 peptide-modified liposomes loaded with doxorubicin (pHCT74-lipo-Dox).
• In vitro assessment of cellular internalization and cytotoxicity in prostate carcinoma cells.
• In vivo studies to evaluate tumor accumulation and anti-tumor efficacy in mice bearing prostate tumors.

Main Results:

• pHCT74-lipo-Dox demonstrated superior intracellular uptake and enhanced cytotoxicity compared to unmodified liposomes.
• In vivo studies showed significantly higher tumor accumulation of pHCT74-lipo.
• Doxorubicin encapsulated in pHCT74-lipo exhibited significantly improved anti-tumor activity in mice.

Conclusions:

• The pHCT74 peptide is effective in creating targeted liposomes for prostate cancer therapy.
• pHCT74-lipo-Dox represents a promising targeted drug delivery system for enhancing prostate cancer treatment.
• This approach holds potential for developing novel therapeutic strategies against prostate cancer.